Antibodies With Specificity for AC133 Antigen
| Antibody . | Immunogen . | Isotype . | AC141PE Cross-Blocking . |
|---|---|---|---|
| AC133 | HSC | IgG1-κ | −− (E) |
| AC139 | WERI-Rb-1 | IgG1-κ | +/− |
| AC140 | WERI-Rb-1 | IgG1-κ | −− |
| AC141 | WERI-Rb-1 | IgG1-κ | +++ |
| AC142 | WERI-Rb-1 | IgG1-κ | +/− |
| Antibody . | Immunogen . | Isotype . | AC141PE Cross-Blocking . |
|---|---|---|---|
| AC133 | HSC | IgG1-κ | −− (E) |
| AC139 | WERI-Rb-1 | IgG1-κ | +/− |
| AC140 | WERI-Rb-1 | IgG1-κ | −− |
| AC141 | WERI-Rb-1 | IgG1-κ | +++ |
| AC142 | WERI-Rb-1 | IgG1-κ | +/− |
AC133 was raised by immunization with hematopoietic stem cells (HSC), and AC139 to AC142 were raised by immunization with the WERI-Rb-1 retinoblastoma cell line.
Abbreviations: +++, complete cross-blocking of AC141PE conjugate by unlabeled AC141; +/−, partial cross-blocking; −−, zero cross-blocking ability; (E), 20% enhancement of AC141PE conjugate binding in the presence of unlabeled AC133 antibody.